Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine.
Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, which encodes a cAMP-activated anion channel expressed in epithelial cells. The most common mutation Delta Phe508 leads to protein misfolding, retention by the endoplasmic reticulum, and degradation. One promising therapeutic approach is to identify drugs that have been developed for other indications but that also correct the CFTR trafficking defect, thereby exploiting their known safety and bioavailability in humans and reducing the time required for clinical development. We have screened approved, marketed, and off-patent drugs with known safety and bioavailability using a Delta Phe508-CFTR trafficking assay. Among the confirmed hits was glafenine, an anthranilic acid derivative with analgesic properties. Its ability to correct the misprocessing of CFTR was confirmed by in vitro and in vivo studies using a concentration that is achieved clinically in plasma (10 microM). Glafenine increased the surface expression of Delta Phe508-CFTR in baby hamster kidney (BHK) cells to approximately 40% of that observed for wild-type CFTR, comparable with the known CFTR corrector 4-cyclohexyloxy-2-{1-[4-(4-methoxybenzensulfonyl)-piperazin-1-yl]-ethyl}-quinazoline (VRT-325). Partial correction was confirmed by the appearance of mature CFTR in Western blots and by two assays of halide permeability in unpolarized BHK and human embryonic kidney cells. Incubating polarized CFBE41o(-) monolayers and intestines isolated from Delta Phe508-CFTR mice (treated ex vivo) with glafenine increased the short-circuit current (I(sc)) response to forskolin + genistein, and this effect was abolished by 10 microM CFTR(inh)172. In vivo treatment with glafenine also partially restored total salivary secretion. We conclude that the discovery of glafenine as a CFTR corrector validates the approach of investigating existing drugs for the treatment of CF, although localized delivery or further medicinal chemistry may be needed to reduce side effects.
Robert
Renaud
R
Physiology Department, McGill University, Montreal, Quebec, H3G 1Y6, Canada.
Carlile
Graeme W
GW
Liao
Jie
J
Balghi
Haouaria
H
Lesimple
Pierre
P
Liu
Na
N
Kus
Bart
B
Rotin
Daniela
D
Wilke
Martina
M
de Jonge
Hugo R
HR
Scholte
Bob J
BJ
Thomas
David Y
DY
Hanrahan
John W
JW
D018712:Analgesics, Non-Narcotic / Q000493:pharmacokinetics*; D000818:Animals; D001682:Biological Availability; D015153:Blotting, Western; D002460:Cell Line; D006224:Cricetinae; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics / Q000378:metabolism*; D005897:Glafenine / Q000493:pharmacokinetics*; D006801:Humans; D010649:Phenylalanine / Q000235:genetics*; D010879:Piperazines / Q000494:pharmacology; D021381:Protein Transport; D011799:Quinazolines / Q000494:pharmacology; D013050:Spectrometry, Fluorescence
C507255:4-cyclohexyloxy-2-(1-(4-(4-methoxy-benzenesulfonyl)piperazin-1-yl)ethyl)quinazoline; D018712:Analgesics, Non-Narcotic; D010879:Piperazines; D011799:Quinazolines; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D005897:Glafenine; D010649:Phenylalanine